Fig. 6.

Antitumor effects of anti-PD-1 combined with HOCl-CDS hydrogel. a Expression of PD-L1 on BMDCs treated with PBS, HOCl-CDS, or HOCl-CDS hydrogel. Data are presented as means ± SEM (n = 3). b Expression of PD-L1 on BMDMs stimulated with PBS, HOCl-CDS, or HOCl-CDS hydrogel. Data are presented as means ± SEM (n = 3). c Schematic diagram of HOCl-CDS hydrogel treatment combined with anti-PD-1 treatment in mice bearing subcutaneous B16–F10 tumors. d Representative photographs of tumors dissected from mice subcutaneously injected with B16–F10. e Tumor growth curves. Data are presented as means ± SEM (n = 5). f Weight of the dissected tumors. Data are presented as means ± SEM (n = 4–5). g Percentages of CD4⁺IFNγ⁺ T cells in the tumor microenvironment. h Percentages of CD8⁺IFNγ⁺ T cells in the tumor microenvironment. i CD8⁺/CD4⁺ T cell ratios. Data are presented as means ± SEM (n = 4–5).